Abstracts
27
have here their limitation and are for such reconstruction until
today not an alternative due to their poor regeneration potential.
Autogenous bone graft harvested from intraoral sites, espe-
cially the retromolar area of the mandible, and used following the
split bone block (SBB) technique is offering many possibilities for
intra operative facilities and stable long-term results. Splitting the
thick cortical block to 2 or 3 thin blocks is augmenting the num-
ber of blocks allowing the reconstruction of larger atrophic crest
and giving a better adaptation to the recipient site with individual
determination of the width and the volume of the grafted area. Fill-
ing the space and gaps between the thin block and the remaining
crest with particulate bone chips is reducing the time needed for
revascularisation of the graft improving its vitality compared to
the original thick block.
Many studies demonstrate that the reconstruction of horizontal
and vertical atrophied crest with thin mandibular blocks in com-
bination with particulate bone grafts, without any biomaterial or
membrane, offer over years, through the high vitality of the grafted
and regenerated bone, a stable periimplant bone level.
15 years results on more of 1300 grafting procedure for
horizontal and vertical bone augmentation present a low compli-
cation rate and showed that changes of the volume of the grafted
bone occurred up to one year after the grafting procedures and
stays stable for more than 15 years. Limited bone resorptions
were observed, especially when the bone block was grafted out-
side the bone contours, but without negative influence on the
definitive treatment. Implants inserted in this grafted bone pre-
sented similar osseointegration as implants placed in non-grafted
bone.
http://dx.doi.org/10.1016/j.ijom.2017.02.099Development of biodegradable future suture
S.G. Kim
Gangneung-Wonju National University, Gangwon-do, Republic
of Korea
Silk suture material is mainly composed of silk fibroin, which is
produced by silkworm
Bombyx mori.
Silk suture is regarded as
non-resorbable material and it is slowly degraded by proteolysis
when it is implanted into body. 4-Hexylresorcinol (4HR) is well
known antiseptics.
In this study, the biodegradability of the 4HR incorporated
silk suture was compared to those of untreated silk suture and
polyglactin 910 suture which is commercially available resorbable
suture. Silk fibroin disc contained 4HR showed anti-septic prop-
erty and this property was maintained after autoclaving. Matrix
metalloproteinase (MMP) can digest wide spectrum of protein
including collagens. 4HR increased MMP-2, -3, and -9 expression
in RAW264.7 cells. MMP-2, -3, and -9 could digest not only silk
fibroin but also silk suture in
in vitro
experiments. The inhibitor
of MMPs could prevent proteolysis of silk fibroin by MMPs. As
a consequence, 4HR incorporated silk suture was rapidly biode-
graded compared to untreated silk suture and with the similar rate
to polyglactin 910 in the animal model. Expression of MMP-2,
-3 and -9 was high in the 4HR incorporated silk suture implanted
site at 12 weeks after implantation.
In conclusion, 4HR-treated silk suture showed similar level of
bio-degradation to polyglactin 910 suture via higher expression of
MMP-2, -3, and -9 in macrophage.
http://dx.doi.org/10.1016/j.ijom.2017.02.100Revised protocol for the management of medication-related
osteonecrosis of the jaw
S.J. Kim
Ewha Womans University, Seoul, Republic of Korea
Medication-related osteonecrosis of the jaw (MRONJ) has been
reported in patients undergoing treatment with bisphosphonates
for osteoporosis, and because of the 10-year half-life of bisphos-
phonates, there is a need for further studies of this extensive
population.
This presentation provides revised protocol based on several
case reports to show the contrast in treatment outcomes and mor-
bidity in patients with MRONJ. The cases involved diagnostic
imaging modalities commonly used in the practice of dentistry:
panoramic radiography and computed tomography and bone scan.
This case reports demonstrate the usefulness of dental diag-
nostic imaging in the detection and management of MRONJ,
corroborate the increasing number of reports regarding high lev-
els of morbidity associated with various MRONJ treatments, and
underscore the danger of performing invasive dental procedures
for patients receiving bisphosphonate therapy.
This report provides information on the high levels of morbid-
ity associated with various MRONJ treatments, and underscores
the danger of performing even simple procedures, such as
denture delivery for patients receiving bisphosphonate therapy.
Once osteonecrosis of the mandible begins, it is nearly impos-
sible to eradicate the condition. Exposed bone, the hallmark
of MRONJ, will remain and may even progress to fracture.
Therefore, prevention of infection and avoiding the need for
surgery form the cornerstone of treatment. To reach the exact
conclusion, long-term follow-up studies and systemic studies are
needed.
The work was supported by the Ewha Global Top5 Grant 2013
of Ewha Womans University.
http://dx.doi.org/10.1016/j.ijom.2017.02.101Recent advances inmolecular-targeted therapy for oral cancer
M. Kioi
Yokohama City University Graduate School of Medicine, Japan
Although the surgery is standard therapy for oral cancer in many
cases, advanced oral cancer is deadly and disfiguring disease for
which better systemic therapy is enormously sought to improve the
mortality and to avoid dysfunction and cosmetic disorder. Despite
recent advances in multimodality therapies for the treatment of
oral squamous cell carcinoma (OSCC), survival rates, functional
outcomes and toxicities of therapy remain poor.
The development of targeted therapies potentially decreased
toxicities and increased selectivity may represent significant
improvement for the efficacy and also as treatment options. Tar-
geted agents currently approved or under investigation for OSCC
include epidermal growth factor receptor (EGFR) monoclonal
antibodies, EGFR tyrosine kinase inhibitors, vascular endothelial
growth factor receptor inhibitors and various inhibitors of other
targets including immune-checkpoint.
In this talk, the recent advances in targeted therapy for OSCC
will be presented, and also our clinical outcome of several targeted
therapies using cetuximab and local therapy will be introduced.
http://dx.doi.org/10.1016/j.ijom.2017.02.102




